TRU-SENTIMENT ยท DeltaNeutral
TNGX Trading Analysis - 11/20/2026 02:57 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
TNGX (Tango Therapeutics Inc.) at $22.01. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $590 vs put $1,313,740. RSI 51.1.
- Symbol
- TNGX
- Price
- $22.01
- Article bias (separate from True Sentiment)
- bearish
- Conviction
- medium
- Published
- 2026-11-20 14:57:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via True Sentiment (Delta 40-60 only) shows Bearish read: call dollar volume $590.00 (0.0%) vs put dollar volume $1,313,740.00 (100.0%). Only 9 of 472 options analyzed met filter (1.9%). Put contracts 1,730 vs call 1. Heavy put conviction suggests downside protection or bearish near-term expectation. This diverges from neutral RSI and slight-bearish MACD, amplifying caution.
Call Volume: $590.00 (0.0%) Put Volume: $1,313,740.00 (100.0%) Total: $1,314,330.00
Key Statistics: TNGX
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-1.37 |
| Market cap | $3.72B |
| Shares outstanding | 169.5M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.99 |
| 52-week low | $8.30 |
| 52-week high | $34.39 |
| Historical volatility | 95.9% |
Ownership & trading
| Institutional ownership | 47.2% |
| Average daily volume | 3.8M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items are provided from general knowledge and are separated from the data-driven analysis below.
- TNGX (Tango Therapeutics) recently presented preclinical data at a major oncology conference, highlighting progress in its precision medicine pipeline targeting BRCA-mutated tumors.
- The company announced a collaboration expansion with a large pharma partner in Q3 2026, potentially de-risking later-stage development costs.
- No near-term earnings date is confirmed in public records, but biotech small-caps like TNGX often see volatility around trial readouts or FDA designations.
- Broader sector rotation out of speculative biotech in November 2026 may have contributed to the stock's pullback from October highs near $27.65.
- Context: Heavy put positioning in the embedded options data may reflect hedging around binary pipeline events rather than pure directional bearishness on fundamentals.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for TNGX:
- Trailing EPS is -1.37, confirming the company is not profitable; trailing PE, forward PE, and PEG are all null, so traditional valuation ratios are not computable.
- Revenue growth, gross/operating/net margins, ROE, and free cash flow are null in the data โ no profitability or efficiency metrics are available.
- Debt-to-equity is null; however, negative EPS and null cash flow metrics suggest cash-burn typical of clinical-stage biotech.
- Market cap is $3,719,537,250.00 with 169,455,000 shares outstanding and institutional ownership at 47.21%.
- Dividend yield is 0.00%; beta is 0.99 (near market volatility); 52-week range is $8.30 to $34.39.
- Average volume is 3,799,000; historical volatility is 95.92%, indicating extreme price swings.
- Analyst consensus, target mean price, and recommendation key are null โ no street consensus in data.
- Fundamentals (loss-making, high volatility) diverge from the neutral-to-soft technical picture (RSI 51.06) and align with the bearish options flow driven by hedging.
Current Market Position
Current price per indicators is $22.79 (as of 2026-11-19 close). Minute bars show the stock opened 2026-11-19 at $22.15, peaked at $23.66, and by 2026-11-20 14:25 traded down to $22.01. Recent session action shows lower highs and lower lows intraday (14:05 $22.21 to 14:25 $22.01). Daily history shows a drop from $25.98 (2026-11-11) to $22.79, with volume on 2026-11-19 at 1,266,649 vs 20-day avg 2,832,069.
Technical Analysis
Technical Indicators
Price ($22.79) is below SMA 5 ($23.34), SMA 20 ($23.11), and SMA 50 ($23.51) โ bearish alignment with no golden cross. RSI 51.06 is neutral. MACD (-0.05) below signal (-0.04) with negative histogram (-0.01) shows mild bearish momentum. Bollinger mid $23.11, price near lower band ($20.63) but above it. 30-day range $20.74โ$27.65; price sits in lower third.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via True Sentiment (Delta 40-60 only) shows Bearish read: call dollar volume $590.00 (0.0%) vs put dollar volume $1,313,740.00 (100.0%). Only 9 of 472 options analyzed met filter (1.9%). Put contracts 1,730 vs call 1. Heavy put conviction suggests downside protection or bearish near-term expectation. This diverges from neutral RSI and slight-bearish MACD, amplifying caution.
Call Volume: $590.00 (0.0%) Put Volume: $1,313,740.00 (100.0%) Total: $1,314,330.00
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.